Figure 5

Plasma CCL17 and CCL22 levels decrease over time in patients who achieve remission of disease. Plasma samples collected every 3 months from seven patients (separate colors) enrolled in an ongoing celecoxib clinical trial who became disease-free for at least 6 months were analyzed for (A) CCL17, (B) CCL22, and (C) CCL18 concentrations via multiplex ELISA. Data is shown relative to time (months) after complete clinical remission. Linear regression was performed for each patient, and a test of repeated measures using severity group as a covariant was employed. CCL17 (p = 0.01) and CCL22 (p = 0.002) strongly correlated with the number of months since remission, CCL18 did not.